Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
about
Perspectives on menopause and women with HIVHIV infection and osteoporosisHIV: inflammation and boneBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoThe effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicityPregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trialAbacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyChanges in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialBone health in HIV and hepatitis B or C infectionsHIV infection and bone disease.Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialLifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependencePer oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients.Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsHIV testing trends: Southeastern Pennsylvania, 2002-2010.HIV-exposed infants: rethinking care for a lifelong condition.The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone healthProspective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy oIncreased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIVPrevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudinePregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trialAntiretroviral therapy: when to startNutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adultsHigher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study.Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients.Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected WomenLess Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
P2860
Q26772852-C89DD6FB-E112-4EC1-AF70-E441187DCDFFQ26853139-9562C2D3-80F5-49FC-AE00-E43551131805Q27010898-CA8EB608-4CE1-423F-930D-35276C0CD3E5Q28476730-B69DB441-AA91-4871-8A3B-65B96686D31AQ28483688-C0DFCFF6-FC9B-43F0-AC28-DD75B580CF73Q28483723-7DDFA229-4DC8-43BA-9AE1-21CC22D8EE53Q28554630-F6D6EBA3-9452-4E82-8BE8-832EEFB59C71Q28728374-68CA8300-8085-4479-B9D6-0AD17F83D5D5Q28730855-43B27121-E67C-42C9-AAED-77E8E055F19DQ30238946-B5A58F3B-66EE-4945-BF2C-80F718B1BBFAQ30249771-0E1B189C-BC2D-4E10-ABA0-AD255CB58D35Q31124706-20965D12-F2E2-4CA6-A087-9B54E9A5D630Q33604322-95FBA99C-C016-43C1-9502-7237ABBC8FBEQ33627227-4914F992-0B50-4B1D-A1E4-A31D65E59C64Q33643157-B1E2F9AF-6350-4B29-8257-95D7278D7241Q33669829-EF454E02-D936-429A-AE75-213FBDAF27E5Q33828318-F621C70B-B42C-4982-9D93-97C3CEFB5C18Q33871174-5E4F33C0-DDBA-4F3C-82E8-5C154B8D0FA6Q34110585-105A970E-4D09-44C8-A994-830AADF7AC70Q34158739-F262534B-01E2-424E-BE68-A61102C3C1D7Q34168353-CF6922BC-C1F1-46D3-BEA4-49F5316EC599Q34264297-C8D82D16-0EF3-4A9B-85D8-C8E6091BC8D8Q34274127-E0F2F242-3093-41A4-B79F-64A16180B653Q34478840-1D64274D-E8A4-474D-940E-C613195A60F7Q35000905-6D5BF2D0-5256-4D2C-A1A0-A3E9132FBEABQ35102114-1A7D8C90-7F1F-427D-BB5A-4FCC2F24E33CQ35124970-1E309259-A0F6-461F-A4C8-74414931EEA5Q35145668-CAD00FF4-1681-47D8-95E1-A7552F94DDC4Q35184560-7CFCBCB3-BED5-4D2C-B7CA-720AB70E1993Q35204279-EDEB8E07-BA5B-4221-83CD-54FE858B4372Q35578707-A645266F-F157-46A6-B3FA-C7D6C6C38726Q35659264-3C9BA29B-CA92-42D0-92C1-9B48C6B0B496Q35743556-5121FE52-9D05-467F-8339-4DB4A480E4A6Q35744467-E2CB0565-95F1-4CCA-9030-C88EA695EC7AQ35815286-2F7CDA9E-2ED4-43EA-B443-725CB7F0705EQ35822412-D7F8F4C8-A53A-404F-8A32-2D7D6C850B6BQ35861528-460141ED-CFDE-4572-97EC-7FD9E7FEAD8EQ35993503-F2C478E3-B46E-4EF5-8686-569320B65ABDQ36030485-A7BA96FC-D709-4406-B21F-6AE759A4B7F1Q36048957-4E10AFEE-B8BB-48A4-AA6F-5B855C50BC1A
P2860
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comparison of changes in bone ...... results from the ASSERT study.
@en
Comparison of changes in bone ...... results from the ASSERT study.
@nl
type
label
Comparison of changes in bone ...... results from the ASSERT study.
@en
Comparison of changes in bone ...... results from the ASSERT study.
@nl
prefLabel
Comparison of changes in bone ...... results from the ASSERT study.
@en
Comparison of changes in bone ...... results from the ASSERT study.
@nl
P2093
P50
P356
P1476
Comparison of changes in bone ...... results from the ASSERT study.
@en
P2093
ASSERT Study Group
David Leather
Eric Van Wijngaerden
Giuliano Rizzardini
Gunta Sture
Hans-Jürgen Stellbrink
Herman G Sprenger
Jan Gerstoft
John Lambert
Juliet Compston
P304
P356
10.1086/656417
P407
P577
2010-10-01T00:00:00Z